PLA2 Lp-PLA2
Selected indexed studies
- Targeting Lp-PLA2 inhibits profibrotic monocyte-derived macrophages in silicosis through restoring cardiolipin-mediated mitophagy. (Cell Mol Immunol, 2025) [PMID:40389600]
- Lp-PLA2 as a biomarker and its possible associations with SARS-CoV-2 infection. (Biomark Med, 2022) [PMID:35694871]
- Lp‑PLA2 in the cancer landscape: From molecular mechanisms to therapeutic potential (Review). (Int J Oncol, 2025) [PMID:40849801]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Targeting Lp-PLA2 inhibits profibrotic monocyte-derived macrophages in silicosis through restoring cardiolipin-mediated mitophagy. (2025) pubmed
- Lp-PLA2 as a biomarker and its possible associations with SARS-CoV-2 infection. (2022) pubmed
- Lp‑PLA2 in the cancer landscape: From molecular mechanisms to therapeutic potential (Review). (2025) pubmed
- [Lp-PLA2 and sPLA2: cardiovascular biomarkers]. (2014) pubmed
- The Value of Lp-PLA2 as a Biomarker for the Diagnosis of Plaque Stability in Atherosclerosis: A Meta-Analysis. (2025) pubmed
- Lp-PLA2: a new kid on the block. (2006) pubmed
- Lp-PLA2: A new target for statin therapy. (2010) pubmed
- Utility of Lp-PLA2 in lipid-lowering therapy. (2012) pubmed
- PLAC Test for Lp-PLA2 Activity to Predict Coronary Heart Disease. (2020) pubmed
- [Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques]. (2016) pubmed